Pomalidomide combinations are a safe and effective option after daratumumab failure.
J Cancer Res Clin Oncol
; 149(9): 6569-6574, 2023 Aug.
Article
em En
| MEDLINE
| ID: mdl-36781500
ABSTRACT
PURPOSE:
Outcomes of multiple myeloma (MM) patients who are refractory to daratumumab are dismal and no standard of treatment exists for this patients' population. Here, we investigate the role of pomalidomide combinations in daratumumab-refractory MM patients.METHODS:
We performed a retrospective analysis of myeloma patients treated at four referral centers (three in Germany and one in Italy). Review chart identified 30 patients with relapsed and refractory myeloma, who progressed during treatment with daratumumab and were treated with pomalidomide-based combinations in the subsequent lines of therapy.RESULTS:
Responses improved from 37% with daratumumab to 53% with pomalidomide. Of seven patients with extramedullary MM (EMM), four achieved a clinical stabilization with pomalidomide, including one patient with a long-lasting complete response. Median progression-free survival and overall survival were 6 and 12 months, respectively. Pomalidomide combinations were well tolerated, no patient discontinued treatment due to adverse events.CONCLUSION:
These data show that pomalidomide-based combinations can be an effective and safe salvage regimen for daratumumab-refractory patients, including those with EMM.Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Talidomida
/
Inibidores da Angiogênese
/
Intervalo Livre de Progressão
/
Anticorpos Monoclonais
/
Mieloma Múltiplo
/
Antineoplásicos
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Cancer Res Clin Oncol
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Alemanha